Phage Therapy Defeats Superbugs; Pertussis at 30-Year High; Blood Test Finds Alzheimer's Earlier

Today's roundup spans a novel anti-infective approach with early clinical proof, an alarming resurgence of a vaccine-preventable illness, a diagnostic advance that could change how dementia is caught, a new window on cancer detection, a vaccine-policy shift for young adults, and updated global guidance on ultra-processed food.

Friday, 21 August: Phage Cocktail Clears Carbapenem-Resistant Infections in ICU Trial

A phase 2 randomised controlled trial published in The New England Journal of Medicine reports that a personalised bacteriophage cocktail cleared active carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in 68 % of ICU patients, compared with 22 % in the standard-of-care arm — the largest controlled trial of phage therapy in critically ill adults to date. The study enrolled 148 patients across eight European hospitals, including one site in Athens. Patients received intravenous phage infusions alongside reduced-dose meropenem for 14 days; the combination lowered 30-day mortality by 19 percentage points. Phage therapy works by deploying viruses that selectively infect and destroy the target bacterium while leaving human cells and commensal bacteria unharmed. The researchers caution that phage matching — identifying which phage strains are active against each patient's isolate — currently takes 48 to 72 hours in specialised laboratories, a bottleneck that must be resolved before the approach can scale. A phase 3 confirmatory trial across 20 European sites is planned for 2027.

Friday, 21 August: Europe Records Its Worst Whooping-Cough Season in Thirty Years

The European Centre for Disease Prevention and Control (ECDC) has reported 87,400 confirmed pertussis cases across EU/EEA member states so far in 2026 — already surpassing the full-year 2012 total that had stood as the post-vaccine-era record. Germany, France, the Netherlands, and Poland account for roughly 60 % of cases, but every EU member state has reported a year-on-year rise. Fifteen infants under three months of age have died, all unvaccinated at the time of illness. That age group is the most vulnerable because the primary infant immunisation schedule cannot begin until six weeks; maternal Tdap vaccination during the third trimester is the only intervention that provides protective antibody before birth. The ECDC is urging all national immunisation authorities to intensify outreach for the pregnancy Tdap booster and to ensure healthcare workers' boosters are current. Unlike measles, immunity to pertussis from both infection and vaccination wanes substantially over a decade, meaning adolescents and adults circulate the bacterium as silent reservoir hosts who then infect unprotected newborns.

Saturday, 22 August: FDA Clears Blood-Based Alzheimer's Test for Primary Care

The U.S. Food and Drug Administration has granted marketing authorisation for a plasma phospho-tau 217 (p-tau217) assay that predicts the presence of amyloid and tau pathology consistent with Alzheimer's disease with a reported 91 % sensitivity and 87 % specificity. It is the first blood-based Alzheimer's test cleared for ordering by community physicians — not only neurologists or memory-clinic specialists. The test was developed by a consortium led by the University of Gothenburg and Lund University and is intended for patients aged 50 and over who present with subjective cognitive complaints and whose clinician is considering further evaluation. A positive result does not diagnose dementia; it indicates that amyloid PET imaging or cerebrospinal fluid biomarker confirmation is warranted. The Alzheimer's Association welcomed the clearance but emphasised that counselling infrastructure and access to disease-modifying therapies must expand in parallel: both anti-amyloid antibodies currently approved in the United States carry specific eligibility criteria and carry significant cost and monitoring requirements. The test is not yet authorised by the European Medicines Agency; a submission dossier was filed in June 2026 and a decision is expected in mid-2027.

Saturday, 22 August: Methylation Liquid Biopsy Detects Early-Stage Ovarian Cancer with 89 % Sensitivity

A multicentre study published in The Lancet Oncology evaluated a cell-free DNA methylation assay in 1,240 women with confirmed early-stage ovarian cancer and 1,580 healthy controls. The test identified stage I and II disease with 89 % sensitivity and 94 % specificity — a substantial improvement over CA-125, the protein marker currently used in symptomatic women, which detects only 50–60 % of early-stage cases. Ovarian cancer carries the highest case-fatality ratio of any gynaecological malignancy in the EU because it is nearly always detected at stage III or IV, when five-year survival drops below 30 %. The authors emphasise that the study enrolled women with already-confirmed diagnoses, not a general-population screening cohort, so the test's performance in asymptomatic women remains unknown. A prospective 25,000-person screening trial funded by Cancer Research UK is expected to begin enrolling in late 2026; results would not be available for several years. No change to clinical guidelines is recommended at this stage, but the signal is considered strong enough to justify the confirmatory trial.

Saturday, 22 August: UK Advisory Body Recommends MenB Vaccine for All University Entrants

The UK Joint Committee on Vaccination and Immunisation (JCVI) has formally recommended extending meningococcal group B (MenB) vaccination to all students entering higher education, citing clustering of cases in first-year students living in shared residential accommodation — the same epidemiological pattern that long ago justified the meningococcal ACWY programme for this age group. Three EU advisory bodies — in Germany, the Netherlands, and Sweden — are reviewing comparable extensions. Meningococcal B bacteria cause approximately one-third of all bacterial meningitis cases in Europe. Incidence is low (roughly 1 in 100,000 per year) but the disease is swift and the consequences severe: case fatality approaches 10 %, and permanent disability including limb loss or brain injury occurs in up to a quarter of survivors. The Bexsero (GSK) and Trumenba (Pfizer) vaccines are licenced across the EU; the outstanding question is whether to fund them within national immunisation programmes for the university-entrant cohort. The JCVI notes that a two-dose schedule given at least three weeks before arrival at university provides seroprotection in time for the highest-risk period. No Cyprus or Greek immunisation advisory has yet commented on a similar extension.

Saturday, 22 August: WHO Evidence Synthesis Links Ultra-Processed Food to Higher Diabetes and Cardiovascular Risk

The World Health Organization has released an updated evidence synthesis on ultra-processed food (UPF) consumption and non-communicable disease burden, drawing on 67 prospective cohort studies encompassing 9.7 million participants across 28 countries. Consumption in the highest quintile is associated with a 23 % higher risk of type 2 diabetes, an 18 % higher risk of cardiovascular mortality, and a 12 % higher all-cause mortality risk relative to the lowest quintile, after adjustment for total energy intake and overall dietary quality. The WHO notes explicitly that these associations are consistent across income groups and world regions but that the synthesis is observational — causation cannot be established from cohort data alone. The synthesis is the empirical foundation for a formal WHO guideline on food processing classification expected in early 2027. For the eastern Mediterranean region, where UPF intake has grown sharply with urbanisation and income growth, particularly among younger age groups, the findings reinforce longstanding public-health messaging around the traditional Mediterranean dietary pattern, which remains strongly associated with lower rates of chronic disease.

This article is journalistic reporting and does not constitute medical advice. Readers should consult a qualified clinician before making any change to their treatment, medication, or health management.